Liothyronine

Nuclear Receptor Binding and Gene Transcription#

Liothyronine is the synthetic form of T3, the biologically active thyroid hormone. Unlike T4 (levothyroxine), it bypasses the peripheral deiodinase conversion step entirely — meaning the effect is immediate and not gated by DIO1/DIO2 activity, nutritional status, or reverse-T3 buildup.

Once inside the cell, T3 binds nuclear thyroid hormone receptors (TRα, TRβ), which heterodimerize with RXR on thyroid response elements (TREs) in DNA. This drives transcription of genes governing basal metabolic rate, mitochondrial density, substrate oxidation, and β-adrenergic receptor expression.

"Thyroid hormone exerts its action by binding to nuclear receptors, regulating gene transcription and thus controlling basal metabolic rate, thermogenesis, and lipid metabolism." — Biondi B, Cooper DS., Endocrine Reviews (2008)

Practical translation: T3 doesn't "burn fat" acutely — it reprograms the cell's transcriptional baseline over 24–72 hours, which is why dose changes take several days to fully express and why abrupt cessation leaves you functionally hypothyroid for weeks.

Cellular Uptake via MCT8/MCT10#

T3 does not diffuse passively into cells at meaningful rates. Active transport via the monocarboxylate transporters MCT8 and MCT10 is rate-limiting for intracellular action, which is why tissue-level effects scale with transporter expression rather than just plasma T3.

"Active transport of T3 into target cells is mediated by specific transporters, such as MCT8 and MCT10, which is critical for intracellular thyroid hormone action." — Hennemann G, Docter R, Friesema EC, de Jong M, Krenning EP, Visser TJ., Endocrine Reviews (2001)

This matters for cycle design: the liver, skeletal muscle, heart, and brown adipose are MCT-rich and respond fast — which is why resting heart rate is the best real-time dosing biomarker you have.

Thermogenesis via Na⁺/K⁺-ATPase and Uncoupling Proteins#

Downstream of TR activation, T3 upregulates Na⁺/K⁺-ATPase density and uncoupling proteins (UCP-2, UCP-3) in skeletal muscle and brown adipose. The ATPase burns ATP maintaining ion gradients; the UCPs dissipate the mitochondrial proton gradient as heat rather than capturing it as ATP.

The net effect is a genuine increase in obligatory thermogenesis — your body runs hotter and less efficiently at rest. This is the mechanism behind the "T3 sweats," the slightly elevated basal temperature on cycle, and the real fat-loss signal. It's also why T3 works even without training volume changes.

β-Adrenergic Receptor Upregulation (The Clen/Albuterol Synergy)#

T3 upregulates β1-adrenergic receptor density in myocardium and adipose tissue. This sensitizes you to endogenous and exogenous catecholamines — meaning the same clenbuterol or albuterol dose hits harder on a T3 base than off it.

This is the pharmacological reason the T3 + clen stack is a contest-prep standard rather than redundant. T3 builds the receptor scaffolding; the β2-agonist activates it. It's also why stacking T3 with high-dose stimulants (clen, yohimbine, ephedrine, heavy caffeine) stops being additive and starts being cardiotoxic — you've multiplied both the receptor count and the signal.

Lipolysis, Proteolysis, and the Catabolism Problem#

At euthyroid replacement doses, T3 is nitrogen-neutral. At the supraphysiologic doses bodybuilders run (50–100 mcg/day), the transcriptional program extends beyond lipolysis into frank proteolysis — hepatic HSL activity rises, adipose lipolysis accelerates, and FFA oxidation climbs, but skeletal muscle proteolysis rises in parallel.

This is the entire reason T3 is coded as muscle-sparing-only-when-stacked. Without a sufficient exogenous androgen signal (testosterone at minimum, trenbolone/masteron preferred for prep), the anabolic backstop that offsets T3-driven proteolysis isn't there, and the scale drops from a mixture of fat and LBM. Running T3 natty or on a weak SARM-only base is how people emerge from a cut looking smaller and softer than they started.

HPT Suppression and Why Tapering Matters#

Liothyronine suppresses endogenous TSH faster and harder than levothyroxine at equivalent metabolic effect, because you're flooding the system with the active hormone directly rather than the prohormone.

"The pharmacokinetics of liothyronine show a pronounced effect on TSH suppression compared to levothyroxine, resulting in a more immediate and robust metabolic response." — Idrees T, Price JD, Piccariello T, Bianco AC., Current Medical Research and Opinion (2024)

Within days of starting, TSH drops and endogenous T4 production winds down. Stop cold turkey from 75 mcg and you're left with a suppressed axis producing little of its own hormone while exogenous T3 clears — a functional hypothyroid window of 2–6 weeks marked by cold intolerance, fatigue, and the infamous "T3 rebound" weight gain. The fix is mechanical, not metabolic: taper down the way you ramped up, and the axis restarts without drama.

Common (most users)#

• Elevated resting heart rate (10–20 bpm at 50 mcg) — expected and not a reason to stop. Track AM HR daily; if it jumps >20 bpm above baseline, hold the dose rather than ramping further.
• Warmth, sweating, heat intolerance — the thermogenic signal doing its job. Hydrate aggressively and add electrolytes, especially if stacked with clen.
• Mild tremor / jittery hands — usually shows up ramping past 50 mcg. Splitting the dose AM/early-PM blunts the peak; dropping caffeine 200–400 mg/day fixes most cases.
• Insomnia if dosed late — take the full dose on waking. T3's plasma t½ is ~24 h so late dosing gains you nothing and costs sleep.
• Appetite increase and occasional hypoglycemic dips — keep protein high and don't run T3 deep into a fasted state without carbs nearby.
• Absorption variability — calcium, iron, fiber supplements, and coffee all blunt uptake. Take T3 on an empty stomach, 30–60 min before food or supplements.

"Liothyronine administration resulted in a peak serum concentration at 2.5 hours post dose, with a plasma half-life of approximately 1 day." — van der Spek et al., Therapeutic Drug Monitoring (2014)

Uncommon (dose-dependent or individual)#

• Muscle loss / strength drop — the defining risk of T3. If the scale is moving but the mirror is going backwards and lifts are collapsing, you're either under-dosed on AAS, over-dosed on T3, or both. Back T3 down to 25 mcg and reassess the androgen base.
• Palpitations, ectopic beats, BP drift upward — common above 75 mcg, especially stacked with tren or clen. Hold dose, pull stims first, recheck BP/HR after 72 h.
• Anxiety, irritability, racing thoughts — dose-dependent; splitting AM/midday helps. If persistent at 50 mcg, your ceiling is lower than average — stay there.
• GI acceleration (loose stools, cramping) — usually settles in a week. Persistent diarrhea above 50 mcg means back off.
• Menstrual irregularity in women — supraphysiologic T3 can disrupt cycles. Reversible on taper.
• TSH fully suppressed, fT3 high on mid-cycle bloods — this is expected, not pathology. Pull labs at week 3–4 to confirm axis is responding as designed, not to panic at the numbers.

"The pharmacokinetics of liothyronine show a pronounced effect on TSH suppression compared to levothyroxine, resulting in a more immediate and robust metabolic response." — Idrees et al., Current Medical Research and Opinion (2024)

Rare but serious#

• Atrial fibrillation / sustained tachyarrhythmia — risk climbs above 75 mcg, particularly in users with existing LVH or on trenbolone. Warning signs: irregular pulse, chest flutter, sudden breathlessness. Stop immediately and get an ECG.
• Angina / ischemic chest pain — T3 raises myocardial oxygen demand. Any chest pain is a hard stop.
• Thyroid storm (supraphysiologic overshoot) — fever, severe tachycardia, agitation, vomiting. Essentially only seen with reckless dose escalation (≥150 mcg) or combining T3 with undiagnosed Graves'. ER-level emergency.
• Adrenal crisis — T3 accelerates cortisol clearance. In a user with undiagnosed adrenal insufficiency, initiating T3 can precipitate collapse. Warning signs: severe fatigue, hypotension, nausea, hypoglycemia in the first week.
• Accelerated bone turnover — only relevant for year-round users; not a concern on 4–8 week runs.
• Rebound hypothyroidism after abrupt cessation — weeks of cold, flat, water-retentive misery. Preventable entirely by tapering over 2 weeks.

Hard contraindications#

• Untreated hypertension, recent MI, unstable angina, or known tachyarrhythmia (especially AFib) — do not run T3.
• Untreated adrenal insufficiency — T3 can trigger adrenal crisis. Glucocorticoid coverage must be established first.
• Pregnancy at supraphysiologic doses — replacement dosing under a clinician is fine; cutting doses are not.
• Eating disorder history — T3 abuse is a recognized pattern and the compound is off the table.
• Stacking high-dose T3 + clen + yohimbine + high-dose caffeine simultaneously — stack stimulants sequentially, not in parallel. HR ceiling is not negotiable.
• Running T3 solo or on a SARM-only base for cutting — not a safety contraindication in the cardiac sense, but a guaranteed way to lose muscle alongside fat. T3 requires an AAS base (testosterone minimum) to be muscle-sparing.

Gender-specific and PCT considerations#

Women typically cap at 25–50 mcg/day in the final prep weeks, often alongside low-dose anavar as the muscle-sparing base. Same ramp-hold-taper rules apply; the dose is lower but the protocol logic is identical. Cycle irregularity is the most common complaint and resolves post-taper. Avoid entirely during pregnancy at supraphysiologic doses.

PCT: T3 itself does not suppress the HPTA, so no PCT is required for T3. The HPT (thyroid) axis restarts on its own within 4–8 weeks of a proper taper — confirm with TSH/fT3/fT4 labs at 4 and 8 weeks off. If the cycle included AAS, run standard PCT for the androgens; T3 does not change that calculus.